← Back to Screener
Biofrontera Inc. Common Stock (BFRI)
Price$1.09
Favorite Metrics
Price vs S&P 500 (26W)8.82%
Price vs S&P 500 (4W)20.40%
Market Capitalization$12.70M
All Metrics
Book Value / Share (Quarterly)$0.90
P/TBV (Annual)0.85x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)13.31%
Cash Flow / Share (Quarterly)$-1.15
Price vs S&P 500 (YTD)87.30%
Gross Margin (TTM)73.71%
Net Profit Margin (TTM)-25.26%
EPS (TTM)$-1.18
10-Day Avg Trading Volume0.12M
EPS Excl Extra (TTM)$-1.18
Revenue Growth (5Y)17.21%
EPS (Annual)$-1.04
ROI (Annual)-69.92%
Gross Margin (Annual)73.71%
Net Profit Margin (5Y Avg)-58.13%
Cash / Share (Quarterly)$0.55
Revenue Growth QoQ (YoY)36.16%
ROA (Last FY)-36.89%
Revenue Growth TTM (YoY)11.75%
EBITD / Share (TTM)$-0.98
ROE (5Y Avg)-251.27%
Operating Margin (TTM)-27.20%
Cash Flow / Share (Annual)$-1.15
P/B Ratio1.21x
P/B Ratio (Quarterly)0.63x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)0.26x
Net Interest Coverage (TTM)-22.36x
ROA (TTM)-52.22%
EPS Incl Extra (Annual)$-1.04
Current Ratio (Annual)1.52x
Quick Ratio (Quarterly)1.21x
3-Month Avg Trading Volume0.36M
52-Week Price Return28.24%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.67
P/S Ratio (Annual)0.30x
Asset Turnover (Annual)1.46x
52-Week High$1.19
Operating Margin (5Y Avg)-57.68%
EPS Excl Extra (Annual)$-1.04
CapEx CAGR (5Y)-35.56%
26-Week Price Return15.71%
Quick Ratio (Annual)1.21x
13-Week Price Return30.54%
Total Debt / Equity (Annual)0.44x
Current Ratio (Quarterly)1.52x
Enterprise Value$10.894
Revenue / Share Growth (5Y)-38.64%
Asset Turnover (TTM)2.07x
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)2.72x
Pretax Margin (Annual)-25.20%
Cash / Share (Annual)$0.55
3-Month Return Std Dev72.39%
Gross Margin (5Y Avg)53.37%
Net Income / Employee (TTM)$-0
EBITDA Interim CAGR (5Y)57.61%
ROE (Last FY)-100.53%
Net Interest Coverage (Annual)-22.30x
EPS Basic Excl Extra (Annual)$-1.04
Receivables Turnover (TTM)6.62x
Total Debt / Equity (Quarterly)0.44x
EPS Incl Extra (TTM)$-1.18
Receivables Turnover (Annual)6.62x
ROI (TTM)14.55%
P/S Ratio (TTM)0.30x
Pretax Margin (5Y Avg)-58.03%
Revenue / Share (Annual)$4.10
Tangible BV / Share (Annual)$0.67
Price vs S&P 500 (52W)-6.40%
Year-to-Date Return91.23%
5-Day Price Return0.00%
EPS Normalized (Annual)$-1.04
ROA (5Y Avg)-52.29%
Net Profit Margin (Annual)-25.26%
Month-to-Date Return34.73%
Cash Flow / Share (TTM)$-19.36
EBITD / Share (Annual)$-0.98
Operating Margin (Annual)-27.21%
LT Debt / Equity (Annual)0.44x
ROI (5Y Avg)-168.96%
LT Debt / Equity (Quarterly)0.44x
EPS Basic Excl Extra (TTM)$-1.18
P/TBV (Quarterly)0.85x
P/B Ratio (Annual)0.63x
Inventory Turnover (TTM)2.72x
Pretax Margin (TTM)-25.20%
Book Value / Share (Annual)$0.90
Price vs S&P 500 (13W)28.16%
Beta0.86x
Revenue / Share (TTM)$3.58
ROE (TTM)26.25%
52-Week Low$0.54
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.13
4.13
4.13
4.13
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
BFRIBiofrontera Inc. Common Stock | 0.30x | 11.75% | 73.71% | — | $1.09 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Biofrontera Inc is a US-based biopharmaceutical company specializing in photodynamic therapy treatments for dermatological conditions. The company commercializes Ameluz, an FDA-approved topical photosensitizer, along with proprietary RhodoLED lamps designed for the treatment of actinic keratoses, which are pre-cancerous skin lesions. This integrated product approach combines pharmaceuticals with medical devices to address a significant market opportunity in dermatology.